St. John’s-based SiftMed has secured $5 million in seed funding to advance its AI-powered software designed to sift through extensive medical documents and identify crucial facts often overlooked by human reviewers, promising faster and more accurate medical claim decisions.
- AI reduces medical claim review from days to hours
- Recent $5M seed round led by Staircase Ventures
- Targets a $26B medical claims review market in North America
What happened
SiftMed announced a $5 million CAD seed financing round led by Toronto’s Staircase Ventures with participation from The51, Pelorus VC, Sandpiper Ventures, and the founders of Verafin. This brings the company’s total funding close to $11 million. The startup’s solution harnesses AI to quickly analyze and structure medical claim documents, significantly cutting the time needed for claim reviews compared to traditional human efforts.
The company’s CEO Holly Hill explained that reviewing medical records by humans typically takes hours or days, while SiftMed can deliver decisions in approximately two hours or less. SiftMed’s technology was inspired by a real case where a critical handwritten nurses’ note helped overturn erroneous medical assumptions, illustrating the potential value in uncovering overlooked evidence in voluminous documents.
Why it matters
Medical claim processing errors are frequent, with one in five claims reportedly mishandled, often due to missed or misinterpreted supporting evidence. Unlike some AI tools criticized for opacity and lack of accountability, SiftMed emphasizes accuracy and thoroughness in its analyses, seeking to reduce wrongful denials and improve claim outcomes for patients and insurers alike.
With a proven team including former Verafin employees and a strong investor base, SiftMed targets the $26 billion North American market for medical claim reviews. The startup’s ability to double revenue every six months suggests strong demand for solutions that address large-scale inefficiencies in health insurer workflows while ensuring critical data is not overlooked.
What to watch next
SiftMed plans to pursue a Series A funding round within the next 12 to 18 months to support expansion. The company also faces a competitive landscape, with other firms like Toronto-based Wisedocs developing similar technologies to automate medical record review, making continuous innovation and strong validation key to long-term success.
As policymakers and patients increasingly express concerns around AI’s role in medical decision-making, SiftMed will need to maintain transparency and integrate meaningful human oversight in its processes. Success will depend on balancing speed and accuracy with stakeholder trust, potentially shaping industry standards for AI-assisted medical claims review.